May 18, 2018 – CRMBM – 2h30 pm
Meeting at 13h00 for the students of the ICN PhD program
Prof. Dr. med. Christian Enzinger finished his studies in Human Medicine at Karl-Franzens-University of Graz, Austria in 1998 and qualified as a neurologist in 2006. He trained in neuroimaging as a Research Fellow at the Centre for Functional MRI of the Brain (FMRIB) at Oxford University, UK from 2004-2005.
He is Associate Professor of Neurology, Deputy Head of the Department of General Neurology at the University Clinic of Graz and Director of the Research Unit for Neuronal Repair and Plasticity at the Medical University of Graz.
Dr. Enzinger is Co-chair of the MAGNIMS group (Magnetic Resonance in MS), president of the Austrian Society for Functional MRI, Board Member of the Alpine Chapter of the OHBM (Organization for Human Brain Mapping) and of IMSCOGS (International Multiple Sclerosis Cognition Society), member of the Scientific Committee of the European Academy of Neurology (EAN) and co-chair of the Scientific Panel Neuroimaging of the EAN. He also organises the national MS academy and has contributed to teaching in the field of MS at various international conferences.
His specific research focus is on the use of MRI to study mechanisms of repair and functional plasticity in MS, ageing and cerebrovascular disease. He has published more than 225 papers in peer-reviewed journals.
“Multiple Sclerosis – MRI research improves diagnosis, management, and increases pathophysiologic insights into a complex disease”
Multiple Sclerosis (MS), a chronic inflammatory disease of the CNS with a neurodegenerative component, remains challenging both for clinicians and researchers, especially due to its heterogeneity concerning pathophysiology, but also clinical and radiological appearances.
Besides its established role in obtaining an early diagnosis of MS, the high sensitivity of magnetic resonance imaging (MRI) of the brain allows assessing the amount of focal MS-related tissue changes. In clinical practice, this information is commonly used to inform therapeutic decisions in early stages of MS, as it captures preceding tissue damage and may predict future disease activity. However, relapsing-remitting MS constitutes a heterogeneous disease. The long-standing course of disease and often subclinical accumulation of tissue changes without overt clinical relapses make it further difficult to judge disease activity merely on clinical grounds. Together, this calls for biomarkers that allow detecting the dynamic changes in the pathological processes involved in MS over shorter periods of time. In this context, repeated MRI of the brain provides an important tool.
Based on the evolution of the diagnostic MRI criteria in MS (revised in 2017) and novel results from more basic MRI research, this presentation will give an overview on recent advances but also highlight unmet needs in this active field of research.
Having expertise both in clinical neurology and neuroimaging research the speaker will critically review the state of the field, seeking to address delegates with different interests at various levels of expertise, and allowing for open and ample discussion.